File(s) under permanent embargo
Beta-blockers in asthma
journal contributionposted on 2023-05-22, 02:11 authored by Luke BereznickiLuke Bereznicki, Bonnie BereznickiBonnie Bereznicki
Australia has one of the highest prevalence rates for asthma in the world, affecting around 15% of the population. Short-acting beta2 agonists (SABAs) have a longstanding role as the main treatment option for the acute relief of symptoms, while more recently long-acting beta2 agonists (LABAs) have been recommended for use as add-on therapy to inhaled corticosteroids for the prevention of symptoms.
Publication titleAustralian Pharmacist
Department/SchoolSchool of Pharmacy and Pharmacology
PublisherPharmaceutical Society of Australia
Place of publicationDeakin West, ACT.
Rights statementCopyright 2013 Pharmaceutical Society of Australia Ltd